Klaus Okkenhaug

Klaus Okkenhaug

University of Cambridge

H-index: 66

Europe-United Kingdom

About Klaus Okkenhaug

Klaus Okkenhaug, With an exceptional h-index of 66 and a recent h-index of 44 (since 2020), a distinguished researcher at University of Cambridge, specializes in the field of Immunology, Cell Signalling, PI3K, Cancer Immunotherapy, Primary Immunodeficiency.

His recent articles reflect a diverse array of research interests and contributions to the field:

Lack of phosphatidylinositol 3-kinase VPS34 in regulatory T cells leads to a fatal lymphoproliferative disorder without affecting their development

An evolutionary-conserved VPS34-PIKfyve-TRPML1-Myosin II axis regulates the speed of amoeboid cell migration

Mind the GAP: RASA2 and RASA3 GTPase-activating proteins as gatekeepers of T cell activation and adhesion

The Toll-like receptor 4 pathway modulates response to anti-PD-1 therapy

An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome

Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance

Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release

Klaus Okkenhaug Information

University

Position

Professor of Immunology Department of Pathology

Citations(all)

23424

Citations(since 2020)

8114

Cited By

18335

hIndex(all)

66

hIndex(since 2020)

44

i10Index(all)

109

i10Index(since 2020)

99

Email

University Profile Page

University of Cambridge

Google Scholar

View Google Scholar Profile

Klaus Okkenhaug Skills & Research Interests

Immunology

Cell Signalling

PI3K

Cancer Immunotherapy

Primary Immunodeficiency

Top articles of Klaus Okkenhaug

Title

Journal

Author(s)

Publication Date

Lack of phosphatidylinositol 3-kinase VPS34 in regulatory T cells leads to a fatal lymphoproliferative disorder without affecting their development

bioRxiv

Christina JF Courreges

Elizabeth CM Davenport

Benoit Bilanges

Elena Rebollo-Gomez

Jens Hukelmann

...

2024

An evolutionary-conserved VPS34-PIKfyve-TRPML1-Myosin II axis regulates the speed of amoeboid cell migration

bioRxiv

Philippe Dehio

Céline Michard

Juan Carlos Yam-Puc

Adrià-Arnau Martí i Líndez

Lucien Fabre

...

2024

Mind the GAP: RASA2 and RASA3 GTPase-activating proteins as gatekeepers of T cell activation and adhesion

Kristoffer H Johansen

Dominic P Golec

Klaus Okkenhaug

Pamela L Schwartzberg

2023/10/17

The Toll-like receptor 4 pathway modulates response to anti-PD-1 therapy

The Journal of Immunology

Sarah K Whiteside

Benjamin S Beresford-Jones

Puspendu Sadar

Paula Kuo

Wangmingyu Xia

...

2023/5/1

An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome

Pulmonary pharmacology & therapeutics

Malcolm Begg

Augustin Amour

Emily Jarvis

Teresa Tang

Sara Santos Franco

...

2023/4/1

Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

Science immunology

Sarah K Whiteside

Francis M Grant

Giorgia Alvisi

James Clarke

Leqi Tang

...

2023/12/15

Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance

bioRxiv

Munetomo Takahashi

Tsz Y So

Kate Williamson

Zhaleh Hosseini

Katarzyna Kania

...

2023/3/20

Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release

EMBO reports

Hazel Stewart

Roberta Palmulli

Kristoffer H Johansen

Naomi McGovern

Ola M Shehata

...

2023/12/6

Tissue-resident B cells orchestrate macrophage polarisation and function

Nature communications

Ondrej Suchanek

John R Ferdinand

Zewen K Tuong

Sathi Wijeyesinghe

Anita Chandra

...

2023/11/4

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

Nature

Simon Eschweiler

Ciro Ramírez-Suástegui

Yingcong Li

Emma King

Lindsey Chudley

...

2022/5/26

BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis

Journal of Experimental Medicine

Charlotte J Imianowski

Sarah K Whiteside

Teresa Lozano

Alexander C Evans

Jayme D Benson

...

2022/9/30

A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1–mediated adhesion in T cells

Science signaling

Kristoffer H Johansen

Dominic P Golec

Bonnie Huang

Chung Park

Julie H Thomsen

...

2022/7/19

How to resist PI3Kδ inhibition: activate MAPK!

Blood, The Journal of the American Society of Hematology

Klaus Okkenhaug

2021/7/8

PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells

Frontiers in Immunology

Daisy H Luff

Katarzyna Wojdyla

David Oxley

Tamara Chessa

Kevin Hudson

...

2021/3/8

Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model

Brain, behavior, & immunity-health

Ines Serra

Olivia R Manusama

Fabian MP Kaiser

Izi Izumi Floriano

Lucas Wahl

...

2021/12/1

CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function

Immunology

Sarah K Whiteside

Francis M Grant

David S Gyori

Alberto G Conti

Charlotte J Imianowski

...

2021/5/9

PI3K inhibitors are finally coming of age

Bart Vanhaesebroeck

Matthew WD Perry

Jennifer R Brown

Fabrice André

Klaus Okkenhaug

2021/10

The GPCR adaptor protein norbin suppresses the neutrophil-mediated immunity of mice to pneumococcal infection

Blood advances

Chiara Pantarelli

Dingxin Pan

Stephen Chetwynd

Anne-Katrien Stark

Kirsti Hornigold

...

2021/8/24

PI3K in T cell adhesion and trafficking

Kristoffer H Johansen

Dominic P Golec

Julie H Thomsen

Pamela L Schwartzberg

Klaus Okkenhaug

2021/8/6

BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression

Journal of Experimental Medicine

Francis M Grant

Jie Yang

Rabab Nasrallah

James Clarke

Firas Sadiyah

...

2020/9/7

See List of Professors in Klaus Okkenhaug University(University of Cambridge)

Co-Authors

H-index: 98
D Cantrell

D Cantrell

University of Dundee

H-index: 90
Emilio Hirsch

Emilio Hirsch

Università degli Studi di Torino

H-index: 90
Bart Vanhaesebroeck

Bart Vanhaesebroeck

University College London

H-index: 75
Kjetil Tasken

Kjetil Tasken

Universitetet i Oslo

H-index: 69
Anton Enright

Anton Enright

University of Cambridge

H-index: 59
Rottapel R

Rottapel R

University of Toronto

academic-engine